Bilcare Ltd., service provider to the pharmaceutical companies spanning across their value chain from drug discovery to market, continues to grow globally.The Board of Directors in their meeting held on 30th June 2008 proposed a dividend of 40%, at Rs 4 per equity share.

The consolidated revenue for the year ended 31st March 2008, stood at Rs 669.92 Cr, registering a growth of 57% over the previous year consolidated revenue of Rs 425.72 Cr.This resulted in a better EBIDTA of Rs 162.71 Cr. for FY08 as against Rs 116.98 Cr. of the previous year registering a growth of 39%.Net Profit for the same period grew by 36% to Rs 81.55 Cr for FY08 as against Rs 59.92 Cr. of the previous year.

The year-end for all subsidiary companies has been brought to a uniform closing to 31st March. As a result of this, for the year ended 31st March 2008 the financials of the overseas subsidiaries are for a period of 15 months, while Bilcare India financials are for a 12-month period.

The India standalone revenue of the company for the current year grew by 24% from Rs 341.44 Cr. in FY07 to Rs 422.12 Cr. FY08. This resulted in EBIDTA growth of 19% from Rs 108.50 Cr. in the previous year to Rs 128.68 Cr. in FY08. The EPS of the company stood at Rs 37.49 in FY08 as against Rs 41.24 in FY07 due to the conversion of outstanding warrants and convertible bonds during the year.

“In last one year, we have significantly invested in creation of knowledge, innovation and technology. Going forward, these three verticals of strategic investments will enable Bilcare Ltd. to emerge as leaders in counterfeit technology, clinical service and packaging solutions.” said Mohan Bhandari, Chairman & Managing Director, Bilcare Ltd.

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• CTE’s cons revenue up by 657% at Rs 44.59cr
• Quintegra’s posts net profit up by 20.40% at Rs 2.18cr
• Nitin Fire cons sales up by 31.71% at Rs 132.42cr
• Batliboi’s cons gross revenue up by 113%, PBT up by 22%
• Sonata cons Q3 Net at Rs 15.7cr up 31% QoQ